Acurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors

Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) is one of the best up and coming penny stocks to buy. On February 2, Acurx Pharmaceuticals announced that the United States Patent and Trademark Office granted a new patent, US 12,534,470, covering its DNA Polymerase IIIC inhibitors. This patent includes compositions-of-matter, methods of use, and pharmaceutical compositions, reinforcing the company’s intellectual property for its ACX-375C program.

To date, Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) has secured four US patents alongside international grants in Israel, Japan, India, and Australia, with further country-level applications currently under review. Executive Chairman Robert J. DeLuccia stated that this patent extends protection for the company’s AI-supported drug discovery platform, which aims to transform the treatment of life-threatening infections.

Acurx Pharmaceuticals (ACXP) Secures New US Patent for DNA Polymerase IIIC Inhibitors

Recent preclinical data suggests that microbiome selectivity may be a class effect of these novel compounds when compared to antibiotics like linezolid. While the lead inhibitor, ibezapolstat, is Phase 3-ready for treating C. difficile, these newer preclinical compounds show potential for systemic absorption via oral and parenteral administration. The company’s pipeline targets various serious conditions, including MRSA, community-acquired bacterial pneumonia, bacteremia, and inhalational anthrax. Acurx focuses on developing a new class of small-molecule antibiotics that inhibit the Gram-positive-specific enzyme DNA polymerase IIIC to cause bacterial cell death.

Acurx Pharmaceuticals Inc. (NASDAQ:ACXP) is a clinical-stage biopharmaceutical company that develops antibiotics to treat bacterial infections in the US. The company’s lead antibiotic candidate is ibezapolstat, which targets the polymerase IIIC enzyme.

While we acknowledge the potential of ACXP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ACXP and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.